VEEV Stock Recent News

Veeva (VEEV) announces the Veeva AI Partner Program, which is expected to provide partners assistance to combine Generative AI solutions with Veeva Vault applications.

Veeva Systems (VEEV) closed the most recent trading day at $201.10, moving +1.02% from the previous trading session.

Veeva Systems is performing well and demonstrating strong management execution, making it a buy. The company's R&D solutions and Veeva Vault CRM migration are key factors for future growth. Veeva's business model is resilient, and it has a strong competitive advantage over competitors like IQVIA and Google/Microsoft in the healthcare industry.

Veeva (VEEV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

The latest trading day saw Veeva Systems (VEEV) settling at $211.19, representing a +0.13% change from its previous close.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Veeva Systems' (VEEV) CFO Brent Bowman steps down, leading analysts to weigh in on the impact and prospects for the cloud-solutions company.

Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.

Veeva Systems' stock price has surged by 21% since June 2023, driven by their data analytics and AI capabilities in the healthcare industry. The company estimates a $20 billion total addressable market, with their Development Cloud accounting for 65% of opportunities. Veeva's clinical platform, which connects clinical operations and data management, is an untapped market that could generate long-term growth.

Veeva Systems is experiencing a technological transition that has impacted its revenue growth and adjusted EBITDA. The company's management has provided guidance for 2025, and based on projections, the stock is considered cheap with a potential 22% premium. The company is going to consolidate its leadership in cloud software in the healthcare industry, exploiting economies of scale and creating higher barriers to entry.